FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q1 2025

Top Holdings146 positions

Checking export access…
Activity:
SPYSPY
PUT

STATE STR SPDR S&P 500 ETF T

3.3M$1.8B8.9%———
Decreased
—

HESS CORP

5.4M$866.5M4.2%——
6 qtrssince 2023-Q4
Decreased
0

MICROSOFT CORP

2.3M$858.1M4.1%$297.44+24.74%
26 qtrssince 2018-Q4
Increased
77

EXELIXIS INC

22.5M$831.9M4.0%$19.40+90.27%
26 qtrssince 2018-Q4
Decreased
0
DFSDFSDelisted

DISCOVER FINL SVCS

4.8M$815.9M3.9%——
5 qtrssince 2024-Q1
Increased
65

UNITEDHEALTH GROUP INC

1.5M$784.5M3.8%$460.93+9.21%
9 qtrssince 2023-Q1
Increased
60

NATERA INC

4.5M$643.1M3.1%$68.91+105.22%
16 qtrssince 2021-Q2
Increased
59

IQVIA HLDGS INC

3.4M$601.5M2.9%$171.49+3.44%
26 qtrssince 2018-Q4
Increased
59

LANTHEUS HLDGS INC

6M$587.9M2.8%$84.86+13.31%
9 qtrssince 2023-Q1
Increased
61

ARAMARK

16.2M$560.7M2.7%$28.25+20.50%
18 qtrssince 2020-Q4
Increased
72

DISNEY WALT CO

5.5M$542.5M2.6%$95.84+1.09%
4 qtrssince 2024-Q2
Increased
66

SALESFORCE INC

2M$527.9M2.5%$225.07+17.65%
22 qtrssince 2019-Q4
Increased
78

AUTODESK INC

2M$522.9M2.5%$294.73-11.23%
2 qtrssince 2024-Q4
Increased
58

INTUIT

840,258$515.9M2.5%$470.13+26.54%
10 qtrssince 2022-Q4
Increased
60

THERMO FISHER SCIENTIFIC INC

1M$515.4M2.5%$467.67+5.82%
22 qtrssince 2019-Q4
Decreased
0

REVOLUTION MEDICINES INC

13.5M$478.6M2.3%$34.68+7.69%
17 qtrssince 2021-Q1
Increased
55
IBBIBB
PUT

ISHARES TR

3.6M$460.4M2.2%———
Unchanged
—

TRANSUNION

5.4M$449.2M2.2%$85.96-4.71%
26 qtrssince 2018-Q4
Increased
54

NEW YORK TIMES CO MTN BE

8.9M$443M2.1%$42.57+13.64%
20 qtrssince 2020-Q2
Increased
64
ITCIITCIDelisted

INTRA-CELLULAR THERAPIES INC

3.1M$403M1.9%——
1 qtr
New
71
$20.9B
AUM
146
Positions
Q1 2025
Filing
HI score · 1.0/5
Quarterly 13F Value Change
+2%Q4'23$21.9B+8%Q1'24$23.6B-1%Q2'24$23.3B-2%Q3'24$22.8B-0%Q4'24$22.8B-9%Q1'25$20.9B
Activity profile
$ moved · Q1'25
New12%Increased29%Decreased31%Exited28%
Composition
Equity vs derivatives
Equity89%Puts11%Calls0%
Holding period
Avg 2.4 years
<1Q8%1-4Q23%1-2Y26%2Y+42%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $20.9B across 146 positions as of Q1 2025. Top holdings: SPY puts (8.9%), HES (4.2%), MSFT (4.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Q1 2025 Summary

Active quarter - 18 new positions, 20 exits, 43 increased. Top move: CRM (INCREASED, conviction 78). Portfolio: $20.9B across 146 positions.

Top holdings by portfolio weight

Total AUM$19B
HES4.16%
MSFT4.12%
EXEL3.99%
DFS3.91%
UNH3.76%
NTRA3.08%
IQV2.88%
LNTH2.82%
ARMK2.69%
DIS2.60%
Other2.53%

Portfolio allocation by GICS sector

Sectors10
Healthcare39.80%
Unknown17.82%
Technology15.14%
Financial Services9.45%
Communication Services8.88%
Industrials6.09%
Real Estate1.76%
Consumer Cyclical0.72%
Consumer Defensive0.34%
Energy0.01%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L45
Conviction44
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+9M shares+$755.7M
7Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q4 2024 → Q2 2026+7.8M shares+$277M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 → Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used